A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC - Archive ouverte HAL Access content directly
Journal Articles Journal of Thoracic Oncology Year : 2021

A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (13) , (13) , (13) , (14, 15, 16)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Abstract

This open-label, phase 1-2 study evaluated the safety and efficacy of rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, plus immune checkpoint inhibitors nivolumab plus or minus ipilimumab in previously treated extensive-stage SCLC (ES SCLC).

Dates and versions

hal-03524459 , version 1 (13-01-2022)

Identifiers

Cite

Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, Jonathan Lehman, Daniel Morgensztern, et al.. A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. Journal of Thoracic Oncology, 2021, 16 (9), pp.1559-1569. ⟨10.1016/j.jtho.2021.02.022⟩. ⟨hal-03524459⟩
46 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More